GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

NCT07588984 · Not yet recruiting

Last updated 2026-05-28

This study tests how a GLP-1 medication combined with behavioral health programs affects weight and metabolic health in adults with obesity or overweight.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 2,310 people Planned (estimated).

Who can join Ages 18–64 · all sexes

Timeline Started 2026-04 · est. completion 2029-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07588984 ↗

Description as written by the study sponsor.

This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.

Treatments tested

Noom Weight also known as Noom Behavioral

App-based behavioral weight management program providing structured educational content, coaching, and self-monitoring tools focused on nutrition, physical activity, and habit formation.
Free Tier Behavioral

Basic free-to-use tier of the Noom app with limited features; no structured behavioral program or medication.
Education-only control Behavioral

Weekly informational newsletters based on the CDC curriculum for 12 months; no structured behavioral program or medication.
Semaglutide also known as Noom standard dose semaglutide Drug

Standard clinical dosing of compounded semaglutide as part of Noom Med GLP-1Rx program per clinical standard of care, combined with behavioral coaching via the Noom app.
Tirzepatide also known as Noom standard dose tirzepatide Drug

Standard clinical dosing of tirzepatide as part of Noom Plus program per clinical standard of care, combined with enhanced behavioral coaching.
Microdose semaglutide Drug

Below-standard clinical dosing (microdose) of compounded semaglutide as part of Noom Med GLP-1Rx Microdose program, combined with behavioral coaching via the Noom app.
Microdose tirzepatide Drug

Below-standard clinical dosing (microdose) of tirzepatide as part of Noom Plus Microdose program, combined with enhanced behavioral coaching.

Main thing measured	Change in Body Weight
Sponsor	Noom Inc.
Conditions studied	Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07588984 ↗